GlassScriptPhysician profile
John F Cooper
NPI 1336183763
$3,215.78
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $533 · 2021: $774 · 2022: $930 · 2023: $446 · 2024: $28.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.81 | 2019-2022 | |
| Pfizer INC. | $349.81 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.32 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $222.34 | 2019-2023 | Pediarix, Shingrix, Bexsero |
| Lilly USA, LLC | $165.79 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $158.41 | 2019-2023 | Wegovy, Saxenda |
| Biohaven Pharmaceutical Holding Company LTD. | $151.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $148.08 | 2019-2023 | Farxiga |
| Abbott Laboratories | $126.06 | 2019-2024 | Eterna |
| Bayer Healthcare Pharmaceuticals INC. | $121.79 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $112.24 | 2021-2022 | |
| Daiichi Sankyo INC. | $94.80 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $81.15 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $78.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.62 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.